Evidence map›Paper›PMID 34279831›Full record

ArticleAdvances in experimental medicine and biology2021

Intestinal Microbiota in the SARS-CoV-2 Infection: What Is Known?

Patrícia Brito Rodrigues, Arilson Bernardo Dos Santos Pereira Gomes, Lívia Moreira Genaro, Lívia Bitencourt Pascoal, Ana Paula Duarte de Souza, Raquel Franco Leal, Marco Aurélio Ramirez Vinolo

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Patrícia Brito RodriguesLaboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology, and Immunology, Institute of Biology, University of Campinas, Campinas, SP, Brazil.
Arilson Bernardo Dos Santos Pereira GomesLaboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology, and Immunology, Institute of Biology, University of Campinas, Campinas, SP, Brazil.
Lívia Moreira GenaroInflammatory Bowel Disease Laboratory, University of Campinas, Campinas, SP, Brazil.
Lívia Bitencourt PascoalInflammatory Bowel Disease Laboratory, University of Campinas, Campinas, SP, Brazil.
Ana Paula Duarte de SouzaLaboratory of Clinical and Experimental Immunology, Infant Center, School of Medicine, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil. ana.duarte@pucrs.br.
Raquel Franco LealInflammatory Bowel Disease Laboratory, University of Campinas, Campinas, SP, Brazil. rafranco.unicamp@gmail.com.
Marco Aurélio Ramirez VinoloLaboratory of Immunoinflammation, Department of Genetics, Evolution, Microbiology, and Immunology, Institute of Biology, University of Campinas, Campinas, SP, Brazil. mvinolo@unicamp.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent of COVID-19, emerged last year in China and quickly spread to millions of people around the world. This virus infects cells in different tissues and causes pulmonary (e.g., pneumonia and acute respiratory distress syndrome), neurological, cardiovascular, and intestinal manifestations, which can be the result of a direct viral effect or secondary to endothelial, thrombotic, or immunological alterations. In this chapter, we discuss recent studies which highlighted the relevance of the intestinal microbiota for other infectious respiratory diseases. We present the "altered microbiota" (dysbiotic) as a point of connection between conditions that are risk factors for the development of severe forms of COVID-19. In addition, we describe the findings of recent studies reporting alterations of microbiota composition in COVID-19 patients and speculate on how this may impact in development of the disease.

Indexed as

COVID-19Gastrointestinal MicrobiomeChinaDysbiosisHumansSARS-CoV-2CoronavirusMicrobiotaSARS-CoV-2Short-chain fatty acids

Identifiers

PMID34279831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.